U.S. Markets closed

China Biologic Products, Inc. (CBPO)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
111.84-0.73 (-0.65%)
At close: 4:00PM EDT
People also watch
BSTCCPHICXDCHOLISKBI

China Biologic Products, Inc.

Jialong International Tower
Room 1801
Beijing 100125
China
86 10 6598 3111
http://www.chinabiologic.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,751

Key Executives

NameTitlePayExercisedAge
Mr. Xiaoying GaoChairman, Chief Exec. Officer and Pres1.4M7.55M66
Mr. Ming YangChief Financial Officer678.5k2.9M45
Mr. Ming YinSr. Corp. VP491.68k3.93M39
Ms. Zhijing LiuCorp. VP233.34kN/A63
Mr. Gang YangCorp. VP and Gen. Mang. of Guizhou Taibang344.25k5.31M52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (pH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; human cytomegalovirus immunoglobulin; human coagulation factor IX; and human fibrin sealant products. The company sells its products directly, as well as through distributors. China Biologic Products, Inc. is headquartered in Beijing, the People’s Republic of China.

Corporate Governance

China Biologic Products, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.